Craig Hallum Issues Positive Forecast for BioLife Solutions (NASDAQ:BLFS) Stock Price

BioLife Solutions (NASDAQ:BLFS) had its price objective raised by Craig Hallum from $30.00 to $32.00 in a report published on Wednesday morning,Benzinga reports. Craig Hallum currently has a buy rating on the medical equipment provider’s stock.

Other analysts also recently issued reports about the company. HC Wainwright assumed coverage on BioLife Solutions in a research report on Monday, September 30th. They set a “buy” rating and a $29.00 price objective for the company. TD Cowen lifted their price target on shares of BioLife Solutions from $20.00 to $26.00 and gave the company a “buy” rating in a research report on Wednesday, July 17th. Finally, Northland Securities upped their price objective on shares of BioLife Solutions from $26.00 to $28.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $27.83.

BioLife Solutions Trading Down 4.5 %

BioLife Solutions stock traded down $1.08 during mid-day trading on Wednesday, hitting $23.03. The company’s stock had a trading volume of 22,793 shares, compared to its average volume of 373,830. The stock’s fifty day moving average is $24.11 and its two-hundred day moving average is $22.73. The company has a current ratio of 2.86, a quick ratio of 1.81 and a debt-to-equity ratio of 0.04. The firm has a market capitalization of $1.06 billion, a PE ratio of -22.75 and a beta of 1.88. BioLife Solutions has a 1 year low of $11.40 and a 1 year high of $28.88.

Insider Transactions at BioLife Solutions

In related news, EVP Aby J. Mathew sold 10,000 shares of BioLife Solutions stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $23.90, for a total value of $239,000.00. Following the completion of the transaction, the executive vice president now owns 317,716 shares in the company, valued at approximately $7,593,412.40. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other BioLife Solutions news, CRO Garrie Richardson sold 3,070 shares of the company’s stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $25.12, for a total transaction of $77,118.40. Following the sale, the executive now owns 114,773 shares in the company, valued at $2,883,097.76. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Aby J. Mathew sold 10,000 shares of the stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $23.90, for a total value of $239,000.00. Following the completion of the sale, the executive vice president now directly owns 317,716 shares in the company, valued at $7,593,412.40. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 27,044 shares of company stock valued at $645,105. 2.20% of the stock is currently owned by corporate insiders.

Institutional Trading of BioLife Solutions

A number of large investors have recently made changes to their positions in BLFS. Louisiana State Employees Retirement System grew its holdings in BioLife Solutions by 4.0% during the 2nd quarter. Louisiana State Employees Retirement System now owns 18,300 shares of the medical equipment provider’s stock worth $392,000 after acquiring an additional 700 shares in the last quarter. GAMMA Investing LLC lifted its position in shares of BioLife Solutions by 29.4% during the 3rd quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider’s stock worth $83,000 after purchasing an additional 748 shares during the last quarter. The Manufacturers Life Insurance Company grew its stake in shares of BioLife Solutions by 5.8% during the second quarter. The Manufacturers Life Insurance Company now owns 13,825 shares of the medical equipment provider’s stock worth $296,000 after purchasing an additional 753 shares in the last quarter. Sei Investments Co. increased its holdings in BioLife Solutions by 1.4% in the first quarter. Sei Investments Co. now owns 60,191 shares of the medical equipment provider’s stock valued at $1,117,000 after buying an additional 839 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD raised its stake in BioLife Solutions by 10.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 15,129 shares of the medical equipment provider’s stock valued at $281,000 after buying an additional 1,374 shares in the last quarter. 93.24% of the stock is currently owned by hedge funds and other institutional investors.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.